BR112018004403A2 - método, aparelho e sistema para radioterapia - Google Patents

método, aparelho e sistema para radioterapia

Info

Publication number
BR112018004403A2
BR112018004403A2 BR112018004403A BR112018004403A BR112018004403A2 BR 112018004403 A2 BR112018004403 A2 BR 112018004403A2 BR 112018004403 A BR112018004403 A BR 112018004403A BR 112018004403 A BR112018004403 A BR 112018004403A BR 112018004403 A2 BR112018004403 A2 BR 112018004403A2
Authority
BR
Brazil
Prior art keywords
isotope
treatment
alpha
purposes
resin
Prior art date
Application number
BR112018004403A
Other languages
English (en)
Inventor
Doke Aniruddha
Srinivas Shyam
Original Assignee
Sirtex Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtex Medical Inc filed Critical Sirtex Medical Inc
Publication of BR112018004403A2 publication Critical patent/BR112018004403A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
    • G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
    • G01T1/02—Dosimeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00529—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

um dispositivo e método para radioembolização no tratamento de células cancerosas no organismo. em modalidades preferidas, uma radiomicroesfera é formada a partir de uma resina onde um isótopo emissor alfa é utilizado para fins tumoricidas. à medida que o emissor alfa decai, os descendentes do decaimento alfa são capturados pela resina. em modalidades adicionais, o dispositivo compreende pelo menos dois isótopos; em que um primeiro isótopo é para fins terapêuticos e um segundo isótopo é para fins dosimétricos. o segundo isótopo é um emissor de pósitron para dosimetria baseada em pet. em modalidades preferidas, uma dose absorvida por radiação pós-tratamento é determinada utilizando a presente invenção, permitindo que tanto o tratamento como a eficácia do tratamento sejam fornecidos a um paciente com câncer.
BR112018004403A 2015-09-06 2016-07-01 método, aparelho e sistema para radioterapia BR112018004403A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201514846817A 2015-09-06 2015-09-06
US15/197,764 US20170065732A1 (en) 2015-09-06 2016-06-30 Method, Apparatus, and System for Radiation Therapy
PCT/US2016/040599 WO2017039822A1 (en) 2015-09-06 2016-07-01 Method, apparatus, and system for radiation therapy

Publications (1)

Publication Number Publication Date
BR112018004403A2 true BR112018004403A2 (pt) 2018-09-25

Family

ID=56507824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018004403A BR112018004403A2 (pt) 2015-09-06 2016-07-01 método, aparelho e sistema para radioterapia

Country Status (10)

Country Link
US (3) US20170065731A1 (pt)
EP (1) EP3344298A1 (pt)
JP (1) JP6942705B2 (pt)
KR (1) KR102651776B1 (pt)
CN (1) CN108367083B (pt)
AU (1) AU2016317082B2 (pt)
BR (1) BR112018004403A2 (pt)
CA (1) CA2997529C (pt)
HK (1) HK1251160A1 (pt)
WO (1) WO2017039822A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134278C (en) * 2018-03-07 2023-08-29 Siemens Medical Solutions Usa, Inc Calibration bias reduction in a pressurized gas ion chanber-based dose calibrator
MX2020012322A (es) * 2018-05-18 2021-01-29 Bard Peripheral Vascular Inc Sistemas y metodos para uso de una herramienta de software de aplicacion de dosimetria para personalizar la seleccion de dosimentria y esferas para planificacion de procedimientos de radioembolizacion.
EP3793678B1 (en) 2018-05-18 2024-09-18 Bard Peripheral Vascular, Inc. Systems and methods for determining flow parameters of administered fluid from radioembolization delivery device
CN118356553A (zh) 2018-05-18 2024-07-19 巴德外周血管股份有限公司 用于两种或更多种流体的独立输送的双级注射器
EP4031195A4 (en) 2019-09-16 2023-11-29 ABK Biomedical Incorporated COMPOSITION OF RADIOACTIVE AND NON-RADIOACTIVE MICROPARTICLES
EP4093720A1 (en) * 2020-01-23 2022-11-30 Radtran LLC Systems and methods for preparing tailored radioactive isotope solutions
EP4148018A4 (en) * 2020-05-07 2024-06-05 Tokyo Institute of Technology SIMPLE ASTATE CONCENTRATION METHOD
CN117257996A (zh) * 2023-07-06 2023-12-22 北京普尔伟业生物科技有限公司 含有放射性微球的混悬液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
US5854968A (en) * 1997-06-09 1998-12-29 Arch Development Corporation Process and apparatus for the production of BI-213 cations
AUPR098300A0 (en) * 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
JP4495453B2 (ja) * 2001-06-22 2010-07-07 ピージー リサーチ ファンデーション，インコーポレーテッド 自動放射性核種分離システム
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
CN101321542A (zh) * 2003-06-20 2008-12-10 巴尔的摩马里兰大学 用于微动脉成像和放射治疗的微颗粒
AU2005215234B2 (en) * 2004-02-20 2009-02-19 Algeta As Alpha-emitting Hydroxyapatite particles
GB0403856D0 (en) * 2004-02-20 2004-03-24 Algeta As Composition
GB2436508C (en) * 2005-01-14 2011-01-26 Europ Organisation For Nuclear Res Cern Method for production of radioisotope preparationsand their use in life science, research, medical application and industry.
US8771640B2 (en) * 2007-07-10 2014-07-08 Reed Selwyn System and method for using glass microspheres containing a positron-emitting isotope to image blood flow and distribute a radiomedical treatment species
CA2739455A1 (en) * 2008-10-20 2010-04-29 Abbott Laboratories Antibodies that bind to il-12 and methods of purifying the same
US20150273089A1 (en) * 2012-09-17 2015-10-01 Bruce N. Gray Method of treating cancer
BR112015032632A2 (pt) * 2013-07-01 2017-07-25 Univ Australian National material marcado radioativamente

Also Published As

Publication number Publication date
HK1251160A1 (zh) 2019-01-25
US20230181774A1 (en) 2023-06-15
AU2016317082A1 (en) 2018-03-22
AU2016317082B2 (en) 2022-01-13
KR20180063080A (ko) 2018-06-11
US20170065732A1 (en) 2017-03-09
CA2997529C (en) 2024-04-09
JP6942705B2 (ja) 2021-09-29
EP3344298A1 (en) 2018-07-11
JP2018534345A (ja) 2018-11-22
WO2017039822A1 (en) 2017-03-09
KR102651776B1 (ko) 2024-03-28
CN108367083A (zh) 2018-08-03
US20170065731A1 (en) 2017-03-09
CN108367083B (zh) 2021-08-06
CA2997529A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
BR112018004403A2 (pt) método, aparelho e sistema para radioterapia
BR112019021822A2 (pt) Terapia de combinação
HRP20190628T1 (hr) Sredstva za liječenje tumora, njihova uporaba i postupak iste
CY1121269T1 (el) Μεθοδος ειδικης για τον ασθενη επιβεβαιωσης της ακτινοθεραπευτικης αγωγης και ποιοτικου ελεγχου
CR20160186A (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
BR112014030730A2 (pt) entrega de produto radiofarmacêutico e sistema de gerenciamento de tubo
BR112019005430A2 (pt) sistema de distribuição de radioisótopo com múltiplos detectores para detectar emissões gama e beta
MY194484A (en) Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
EP2569054A4 (en) DEVICE, METHOD AND SYSTEM FOR MEASURING PROMPT GAMMA OR OTHER RADIATION-INDUCED RADIATION DURING HADRONTHERAPY TREATMENTS FOR DOSAGE AND RANGE TESTING USES BY IONIZATION RADIATION RECOGNITION
WO2014116665A3 (en) Directed x-ray fields for tomosynthesis
BR112015032632A2 (pt) material marcado radioativamente
Petersson et al. Dosimetry of ultra high dose rate irradiation for studies on the biological effect induced in normal brain and GBM
D'agostino et al. Peripheral doses in radiotherapy: A comparison between IMRT, VMAT and Tomotherapy
AR112405A1 (es) Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas
Jahangiri et al. The effect of field size and distance from the field center on neutron contamination in medical linear accelerator
WO2014033112A3 (de) Dosismessvorrichtung
Nadealian-Dastjerdi et al. Photoneutron shielding design for an 18 MV Saturne 20 medical linear accelerator
Zanzonico Basic sciences of nuclear medicine
Reyes S et al. Dosimetric characterization of a 2-D array of 223 solid state detectors for daily morning checks in Tomo Therapy equipment
Girardi et al. Small fields dosimetry: Output factors and correction factors determination for an elketa axesse medical linac equipped with circular cones
RU2017108562A (ru) Способ получения радиофармпрепарата для лечения онкологических заболеваний
Benali Comparative study by monte carlo simulation of RPL GD-301, TLD-100 and Al2O3: C detectors responses
Park et al. Development of two-dimensional prompt-gamma measurement system for verification of proton dose distribution
Park et al. The effect of photoneutron dose in high energy radiotherapy
Andersson et al. The influence of circadian rhythm on the biodistribution of I-131

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]